Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (March 2021)
33 slides from Cocrystal Pharma's investor presentation, Mar 9, 2021
Slide 1: Investor Presentation March 2021
NASDAQ: COCP. cocrystalpharma.com CCRYSTAL | Investor Presentation PHARMA,INC. March 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. (“Merck”), including the anticipated charac
Slide 3: About Cocrystal Pharma
LD About Cocrystal Pharma Clinical-Stage Antiviral Company Influenza Proprietary Drug Discovery Platform GENER Merck Collaboration Hepatitis C Potential For Prophylactic and rapes ye Pace Norovirus Gastroenteritis
Slide 4: Investment Highlights
N ¢ Investment Highlights I N e Applying proprietary structure-based drug design technology to develop first- and best- in-class broad-spectrum antiviral drugs e Large market opportunities for the treatment of acute and chronic viral diseases including seasonal and pandemic influenza, COVID-19, hepa
Slide 5: Management and Scientific Advisory Board
Manageme: Gary Wilcox, Ph.D. Chairman and Chief Executive Officer + 35+ years of executive biotech leadership experience; played key role in Cialis development Sam Lee, Ph.D. President + 25+ years of anti-infective drug discovery research experience; played key role in early development of phosphoin
Slide 6: Technology Platform
Technology Platform Based on Nobel Prize-winning technology * Near-atomic resolution + X-ray quality crystal production + Drug pocket selection * Hit-to-lead process + Lead optimization EEEEE ¢ Drug candidates Proprietary Technology and Drug Discovery Platform Drug Discovery Platform Crystal Product
Slide 7: Robust Development Pipeline in High-Value Indications
Robust Development Pipeline in High-Value Indications Program Discovery | Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Influenza A/B_ | Influenza A/B inhibitor i> ‘In collaboration with C=) MERCK nfluenza mn > Influenza A PB2 Inhibitor fies Ait CDI-45205 (Diconsed irom Protease Inhibitor KSURF) cov
Slide 8: Overview | Antiviral Program: Influenza A/B Merck Collaboration
Overview | Antiviral Program: Influenza A/B Merck Collaboration
Slide 9: Influenza A/B Merck Collaboration
POS Lol Influenza A/B Merck Collaboration & MERCK Influenza A/B Crystals ¢ Broad-spectrum, potent dual influenza A/B drug candidates ¢ Binds to highly conserved site of influenza A and B replication complex ¢ Expected to be active against seasonal, pandemic and existing drug- resistant influenza A a
Slide 10: Merck Collaboration Terms Overview
AN ; Lol Collaboration Terms Overview Eligible to receive up to $156 million in milestone payments + royalties on product sales « Exclusive worldwide license and collaboration agreement to discover and develop proprietary influenza A/B antiviral agents signed in January 2019 « Agreement structure du
Slide 11: Overview | Antiviral Program: COVID-19
1 Overview | Antiviral Program: COVID-19
Slide 12: Kansas State University Research Foundation Agreements
até 1S ol Kansas State University Research Foundation Agreements Cocrystal acquired exclusive patent rights and know-how for coronavirus and norovirus therapeutics for human use e License agreements with KSURF in 2020 to further develop proprietary broad-spectrum compounds for coronavirus and norovi
Slide 13: Status of COVID-19 Treatment
N S TF Status of COVID-19 Treatment Cocrystal is researching and developing multiple options needed to prevent or treat COVID-19 There is no approved COVID-19 antiviral prophylactic treatment There is no effective COVID-19 antiviral therapeutic treatment 13 C@CRYSTAL
Slide 14: Stages of COVID-19
POSS LT. Stages of COVID-19 xT Stage | Stage II Stage Ill (Early Infection) (Pulmonary Phase) (Hyperinflammation Phase) IIA Viral response phase ' Host inflammatory response phase Time course Severity of Illness Mild constitutional symptoms Shortness of breath without ARDS Clinical Symptoms Fever >9
Slide 15: COVID-19 Program Status
POS Lol COVID-19 Program Status * Potential to be effective treatment for COVID-19 * Develop SARS-CoV-2 inhibitors using proprietary platform technology * Targeting viral replication complex and protease * Potential first-in-class therapeutic and prophylactic treatment Achieved Milestones and Next S
Slide 16: Overview | Antiviral Program: Pandemic Influenza A
16 Overview | Antiviral Program: Pandemic Influenza A
Slide 17: Significant Need for Pandemic Influenza Therapies
POS Lol Significant Need for Pandemic Influenza Therapies Seasonal and pandemic infections 4 Billion 3-5 Million Up to 650,000 cases of severe deaths worldwide cases annually? : y illness annually’ annually’ Current antiviral treatments are burdened by significant viral resistance Approved influenza
Slide 18: Influenza Remains a Major U.S. and Global Concern
~“ oe Fitness | V\ Flu season deaths top 80,000 last year, CDC says Influenza Remains a Major U.S. and Global Concern September 27, 2018 US on track for one of TV the worst flu seasons in decades Jan. 6, 2020 Science Swine flu strain with human pandemic potential increasingly found in pigs in China
Slide 19: CC-42344: Influenza A Pandemic Antiviral Drug
N ry CC-42344: Influenza A Pandemic Antiviral Drug qe Influenza A Crystals Binds to the highly conserved pocket on replication enzyme Exhibits broad spectrum activity against seasonal and pandemic influenza strains Favorable preclinical safety profile and pharmacokinetic properties Multiple routes o
Slide 20: CC-42344 Shows Strong Synergistic Effects with Approved Influenza Antivirals
roi CC-42344 Shows Strong Synergistic Effects with TF Approved Influenza Antivirals Polymerase Inhibitor Favipiravir = In vitro combination studies with Xofluza, Tamiflu, . and Favipiravir demonstrated strong synergistic —— effects -_ =" CC-42344 shows high barrier to drug resistance and active agai
Slide 21: CC-42344: Pharmacological, Safety, Toxicity and PK Evaluations Completed
roi CC-42344: Pharmacological, Safety, Toxicity and ——_ PK Evaluations Successfully Completed In vitro antiviral profiling against seasonal and pandemic influenza A strains Cytotoxicity including larger screen: HepG2/high content analysis and 13 cell lines Caco-2 bidirectional permeability CYP inhib
Slide 22: Overview | Antiviral Program: Hepatitis C
22 Overview | Antiviral Program: Hepatitis C
Slide 23: Hepatitis C Strategy
SS LT. Hepatitis C Strategy _TF Lead program CC-31244, Phase 2a study completed for the treatment of HCV Current HCV Market Overview Evolution of Shorter Therapy ° Ultrashort treatment strategy Nucleoside/NSSA Inhibitors Protease/NSSA Inhibitors * Limitations of existing long-term HCV therapies: * L
Slide 24: CC-31244: HCV Non-Nucleoside Inhibitor (NNI)
N S Lol CC-31244: HCV Non-Nucleoside Inhibitor (NNI) 4 'S5B Polymerase Crystals Next Generation Combination (Cocktail) Therapy Potential Best-in-Class NNI ¢ Potential best-in-class HCV NNI with a - Treatment strong profile SS Frequency ¢ Broad-spectrum, potent NS5B polymerase cc-31244 —, (3.0) inhib
Slide 25: Favorable HCV Phase 2a Trial Results with CC-31244
A \. 1S! Favorable HCV Phase 2a Trial Results with CC-31244 6 weeks of Epclusa® therapy including 2 weeks of CC-31244 Treatment was well tolerated with no study discontinuations due to adverse events 8 of 12 subjects (67%) achieved both SVR12 and SVR24, considered virologic cure 4 patients had virol
Slide 26: Overview | Antiviral Program: Norovirus Gastroenteritis
26 Overview | Antiviral Program: Norovirus Gastroenteritis
Slide 27: Norovirus: No Approved Treatment
Ate Lol Norovirus: No Approved Treatment Norovirus Polymerase and Protease Crystals Estimated annual cost of $60 billion worldwide due to healthcare costs and lost productivity’ 19-21 Million cases in the U.S.1 infections worldwide annually’ 465,000 emergency department visits in the U.S.1 109,000 h
Slide 28: Potential for Developing First Norovirus Therapy
POS Lol Potential for Developing First Norovirus Therapy ¢ Potent, broad-spectrum polymerase and protease inhibitors licensed from KSURF ¢ Structure-based lead molecule discovery ongoing Achieved Milestones and Next Steps: ¥ Q2 2020 Filed Additional Patent Application * H12021 Complete Proof-of-Conc
Slide 29: Positioned for Growth
29 Positioned for Growth
Slide 30: Expanding Intellectual Property Portfolio
mS LD Expanding Intellectual Property Portfolio _TF * Influenza A/B HCV * Influenza A/B inhibitor NS5B (NNI) * Pending applications in U.S. and Issued patents in U.S. worldwide , als : Pending applications in U.S. and F worldwide * Coronavirus i a. * Issued patents in U.S. and major countries Pendin
Slide 31: Financial Snapshot
N Cf Financial Snapshot 4 N ~$110 Million 3.5 Million Average 3 month MEME EES daily share volume’ eee Mules 70.6 Million Fully diluted shares Common shares outstanding ° Clean balance sheet ¢ ~$800,000/month 2021 cash burn ¢ No preferred shares * Cash runway beyond 2022 « No debt * Only 243,000 war
Slide 32: Investment Highlights
N ¢ Investment Highlights I N e Applying proprietary structure-based drug design technology to develop first- and best- in-class broad-spectrum antiviral drugs e Large market opportunities for the treatment of acute and chronic viral diseases including seasonal and pandemic influenza, COVID-19, hepa
Slide 33: Thank you!
NASDAQ: COCP. cocrystalpharma.com C@CRYSTAL Thank you! PetieA ReM AS, I NC.
Cocrystal Pharma — Investor Presentation (March 2021) on 6ix